The aim of this study was to establish the importance of detecting fluoroquinolone (FQ) resistance in multidrug resistant (MDR) Mycobacterium tuberculosis, and to show the usefulness of a hybridization-based line probe assay (LiPA) for detecting gyrA mutations. Thirty-three MDR M. tuberculosis isolates were collected from a total of sixty MDR isolates identified in Japan over 6 months during a national surveillance study in 2002. Seventeen MDR isolates were collected by the National Center for Global Health and Medicine in Japan over 6 years from 2003 to 2008. These 50 isolates were examined for FQ susceptibility, and analysed by LiPA and gyrA sequencing. Among them, 22 (44 %) showed FQ resistance. All FQ-resistant isolates had at least one mutation in gyrA. The results of the LiPA were fully consistent with the DNA sequencing results. Given that on the basis of our results almost half of the MDR M. tuberculosis isolates in Japan might have resistance to FQ, it is important to monitor FQ resistance in patients with MDR tuberculosis (TB), as well as with drug-susceptible TB, prior to commencing treatment. For the detection of FQ resistance, LiPA is useful and can rapidly and efficiently assess FQ resistance.
INTRODUCTION
The emergence and spread of drug-resistant strains of Mycobacterium tuberculosis are a serious threat to the control of tuberculosis (TB), and constitute an increasing publichealth problem (Caminero, 2010; Johnston et al., 2009; Sotgiu et al., 2009; Van Deun et al., 2010a) . Multidrug resistant (MDR) strains are defined as strains resistant to both rifampicin and isoniazid, and extensively drugresistant strains are defined as MDR plus resistance to any fluoroquinolone (FQ) and to at least one of the second-line injectable drugs. Patients infected with these strains are difficult to cure and are more likely to remain infected for a longer period of time than patients with drug-susceptible strains (Caminero, 2010; Johnston et al., 2009; Sotgiu et al., 2009) . With the emergence of MDR and extensively drugresistant TB, the need for rapid drug susceptibility testing is now apparent (Van Deun et al., 2010a) .
FQ is a class of antimicrobial drug with strong activity against M. tuberculosis and is one of the most important second-line antituberculosis drugs used in the treatment of MDR TB (Yew et al., 2010) . Newer FQs, including gatifloxacin (GFLX) and moxifloxacin (MFLX), have been developed. A prospective study (Van Deun et al., 2010b) indicated that a treatment regimen including GFLX was highly effective for MDR TB. A phase II trial study (Conde et al., 2009) showed that a regime including MFLX improved culture conversion in the initial treatment of TB.
The main target of FQ in M. tuberculosis is the DNA gyrase encoded by gyrA and gyrB, which is essential for DNA supercoiling (Guillemin et al., 1998) . The genetic mechanism of FQ resistance is mainly due to alterations in the DNA gyrase, especially mutations in a short sequence called the quinolone-resistance-determining region (QRDR) of the gyrA (Guillemin et al., 1998) .
In this study, 50 MDR M. tuberculosis isolates collected in Japan were examined for FQ susceptibility and analysed by gyrA sequencing. Furthermore, we developed and evaluated a hybridization-based line probe assay (LiPA) for the rapid detection of gyrA mutations, which can easily be used in clinical applications. The whole procedure takes only 9 h, and the estimated cost per sample is £22 (US $35).
We found that nearly half of our Japanese MDR M. tuberculosis isolates had resistance to FQ. Therefore, it is important to detect FQ resistance in patients with MDR TB, as well as with drug-susceptible TB, prior to commencing treatment. FQ susceptibility testing. Drug susceptibility testing was performed at two institutions [33 isolates at the Japan Anti-Tuberculosis Association (JATA) and 17 at the NCGM]. Susceptibility to levofloxacin (LVFX), sparfloxacin (SPFX) and ciprofloxacin (CPFX) was determined at JATA, and susceptibility to LVFX was determined at the NCGM. A broth dilution method (BrothMIC MTB-I; Kyokuto) was used at JATA, and an agar proportion method with egg-based Ogawa medium (Vit Spectrum-SR; Kyokuto) was used at the NCGM. The proportion method is based on a slight modification of the World Health Organization protocol (Aziz et al., 2003) and is recommended by the Japanese Society for Tuberculosis (Aziz et al., 2003; Fujiki, 2001) . The results are shown in Table 1 .
METHODS
Isolation of genomic DNA. Genomic DNA was extracted from bacteria as described previously (Sekiguchi et al., 2007b) .
PCR and DNA sequencing. The QRDR of gyrA was amplified and sequenced by a previously described method (Sekiguchi et al., 2007a) . DNA sequences were compared with H37Rv using GENETYX-MAC, version 14.0.2 (Genetyx).
LiPA. The LiPA was performed as described previously (Ando et al., 2010; Sekiguchi et al., 2007b) . Seven oligonucleotide probes were designed for the LiPA to detect gyrA mutations (Table 2) . Two oligonucleotide probes, S1 and S2, were designed to cover the entire QRDR of gyrA of H37Rv. S2 also contained another probe to compensate for a neutral mutation of G to C at nucleotide position 284 (S95T) (Zhang & Telenti, 2000) . The remaining five oligonucleotide probes, R1-R5, were designed to detect five mutations that were reported previously in FQ-resistant isolates obtained in Japan (Sekiguchi et al., 2007a) . These probes were immobilized on strips of nitrocellulose membrane. The QRDR of gyrA was amplified by nested PCR. Immobilized probes were hybridized with the biotinylated PCR products, and then incubated with streptavidin labelled with alkaline phosphatase. The results were visualized using colour development after incubation with 5-bromo-4-chloro-39-indolylphosphate p-toluidine and nitro blue tetrazolium. The presence or absence of bands on all strips was determined visually. Among the 20 bacterial strains described above, 2 strains of M. tuberculosis and M. bovis were positive for PCR, but the other 18 strains were negative. The PCR products from the two strains hybridized with the S probes, but not the R probes (data not shown). These data indicated that the LiPA is specific for M. tuberculosis and M. bovis. The sensitivity of the LiPA was 24.2 fg M. tuberculosis DNA, equivalent to five copies of gyrA (data not shown).
RESULTS AND DISCUSSION
Fifty MDR M. tuberculosis isolates were collected. Of them, 33 were collected from a total of 60 MDR isolates identified in Japan over 6 months during the national surveillance study in 2002, and 17 were collected in the NCGM in Japan over 6 years from 2003 to 2008. These isolates and H37Rv were examined for FQ susceptibility, and 22 (44 %) of the isolates were resistant to FQ (Table 1) . Among the 33 MDR isolates analysed at JATA, 14 (42 %) were resistant to all three FQs used, i.e. LVFX, SPFX and CPFX. None of the isolates were resistant to only one or two of these FQs ( (Table 1 ). There were no differences in rates of FQ resistance in MDR isolates between the two institutions (P50.4).
We examined whether the MDR isolates had mutations in the QRDR of gyrA by LiPA and DNA sequencing analysis. Hybridization signals visualized as violet bands on the strips were strong and readily discernible with low background (data not shown). As shown in Table 1 , regarding the FQ-resistance profile, the LiPA yielded results that were 100 % in agreement with those obtained by culture-based susceptibility testing. Of the 50 isolates, 28 were positive for both S1 and S2, and the remaining 22 were negative for one of the S probes (DS1 or DS2 in Table  1 ). Of the 22, 4 were positive for R1 indicating that isolates 
ND, Not determined; R, resistant to LVFX; S, sensitive to LVFX; WT, wild-type. *D indicates a negative signal for the probe. DS and R results were determined by the agar proportion method.
had an A90V mutation, 8 were positive for R4 (D94G mutation) and 9 were positive for R5 (D94A mutation). However, one isolate, NCGM2803, with DS2 was negative for R1-R5 indicating that the LiPA could not identify a mutation associated with FQ resistance. As shown in Table  1 , the DNA sequencing data were fully consistent with results obtained by culture-based susceptibility testing. The FQ-resistant NCGM2803 isolate had a mutation of g280t (D94Y). In addition, it was reported that FQ-resistant isolates had mutations in gyrB but not in gyrA (Aubry et al., 2006) . Therefore, the present LiPA will be improved to detect the mutations.
The number of the MDR isolates used in this study is enough to allow estimation of the rate of FQ resistance in Japan. We tested 33 of 60 MDR isolates collected in the national surveillance study. JATA reported that there were 11 933 cases positive for sputum smear in Japan in 2002 (www.jata-org.jp). Whereas, 3122 isolates were collected for 6 months in 2002 during the national surveillance study (TRC, 2007) . It is estimated that the number of isolates collected in the study covered more than 50 % of cases positive for sputum smear. Of the 3122 isolates, 60 isolates were reported to be MDR (TRC, 2007) .
Occasional monitoring of the drug susceptibility of patients with MDR TB before and during chemotherapy is essential as MDR isolates can easily acquire resistance to additional antituberculosis drugs. We reported previously that more than 50 % of MDR isolates have already acquired PZA resistance (Ando et al., 2010) . In the present study, we found that nearly half of our Japanese MDR M. tuberculosis isolates were resistant to FQ. However, little information is available regarding resistance to other second-line drugs, and it will be necessary in future to monitor susceptibility to these drugs.
We strongly suggest that FQ susceptibility needs to be monitored as soon as patients are diagnosed with TB, because FQs are widely used for the treatment of bacterial infections. A population of patients with TB who received FQ treatment have been reported by Wang et al. (2006) . Some other TB patients were initially treated as having community-acquired pneumonia and were administered FQs (Yoon et al., 2005) . We could not obtain information about the TB patients whose isolates were tested in the present study, especially about their previous treatments with antituberculosis drugs, including FQs. Nevertheless, it is very likely that these patients received FQs. In Japan, FQs were used for patients with TB, especially MDR TB, before 2008 but LVFX, MFLX, GFLX, SPFX and CPFX were not officially recommended as antituberculosis drugs by the Japanese Society for Tuberculosis until 2008.
It is also necessary to develop a rapid and inexpensive diagnostic method to determine the drug susceptibility of M. tuberculosis. The whole procedure of the LiPA described here takes only 9 h, and the estimated cost per sample is £22 (US $35). A DNA sequencing-based method (Sekiguchi et al., 2007a) is also rapid, but is more expensive than the LiPA. Therefore, the LiPA is suitable for this purpose. Clinical trials for in vitro diagnosis including non-MDR TB are in progress in Japan. 
